123 related articles for article (PubMed ID: 32578143)
1. Advances in Human Stem Cells and Genome Editing to Understand and Develop Treatment for Fragile X Syndrome.
Zhao X; Bhattacharyya A
Adv Neurobiol; 2020; 25():33-53. PubMed ID: 32578143
[TBL] [Abstract][Full Text] [Related]
2. One-Step Generation of Seamless Luciferase Gene Knockin Using CRISPR/Cas9 Genome Editing in Human Pluripotent Stem Cells.
Li M; Hunt JFVS; Bhattacharyya A; Zhao X
Methods Mol Biol; 2019; 1942():61-69. PubMed ID: 30900175
[TBL] [Abstract][Full Text] [Related]
3. microRNAs and Fragile X Syndrome.
Lin SL
Adv Exp Med Biol; 2015; 888():107-21. PubMed ID: 26663181
[TBL] [Abstract][Full Text] [Related]
4. Integrative Analysis Identifies Key Molecular Signatures Underlying Neurodevelopmental Deficits in Fragile X Syndrome.
Utami KH; Skotte NH; Colaço AR; Yusof NABM; Sim B; Yeo XY; Bae HG; Garcia-Miralles M; Radulescu CI; Chen Q; Chaldaiopoulou G; Liany H; Nama S; Peteri UA; Sampath P; Castrén ML; Jung S; Mann M; Pouladi MA
Biol Psychiatry; 2020 Sep; 88(6):500-511. PubMed ID: 32653109
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic modifications in human fragile X pluripotent stem cells; Implications in fragile X syndrome modeling.
Gerhardt J
Brain Res; 2017 Feb; 1656():55-62. PubMed ID: 26475977
[TBL] [Abstract][Full Text] [Related]
6. Across Dimensions: Developing 2D and 3D Human iPSC-Based Models of Fragile X Syndrome.
Lee A; Xu J; Wen Z; Jin P
Cells; 2022 May; 11(11):. PubMed ID: 35681419
[TBL] [Abstract][Full Text] [Related]
7. Human pluripotent stem cell models of Fragile X syndrome.
Bhattacharyya A; Zhao X
Mol Cell Neurosci; 2016 Jun; 73():43-51. PubMed ID: 26640241
[TBL] [Abstract][Full Text] [Related]
8. Partial FMRP expression is sufficient to normalize neuronal hyperactivity in Fragile X neurons.
Graef JD; Wu H; Ng C; Sun C; Villegas V; Qadir D; Jesseman K; Warren ST; Jaenisch R; Cacace A; Wallace O
Eur J Neurosci; 2020 May; 51(10):2143-2157. PubMed ID: 31880363
[TBL] [Abstract][Full Text] [Related]
9. Reversion of FMR1 Methylation and Silencing by Editing the Triplet Repeats in Fragile X iPSC-Derived Neurons.
Park CY; Halevy T; Lee DR; Sung JJ; Lee JS; Yanuka O; Benvenisty N; Kim DW
Cell Rep; 2015 Oct; 13(2):234-41. PubMed ID: 26440889
[TBL] [Abstract][Full Text] [Related]
10. Reactivation of FMR1 by CRISPR/Cas9-Mediated Deletion of the Expanded CGG-Repeat of the Fragile X Chromosome.
Xie N; Gong H; Suhl JA; Chopra P; Wang T; Warren ST
PLoS One; 2016; 11(10):e0165499. PubMed ID: 27768763
[TBL] [Abstract][Full Text] [Related]
11. High-Throughput Screening to Identify Compounds That Increase Fragile X Mental Retardation Protein Expression in Neural Stem Cells Differentiated From Fragile X Syndrome Patient-Derived Induced Pluripotent Stem Cells.
Kumari D; Swaroop M; Southall N; Huang W; Zheng W; Usdin K
Stem Cells Transl Med; 2015 Jul; 4(7):800-8. PubMed ID: 25999519
[TBL] [Abstract][Full Text] [Related]
12. Molecular analyses of neurogenic defects in a human pluripotent stem cell model of fragile X syndrome.
Boland MJ; Nazor KL; Tran HT; Szücs A; Lynch CL; Paredes R; Tassone F; Sanna PP; Hagerman RJ; Loring JF
Brain; 2017 Mar; 140(3):582-598. PubMed ID: 28137726
[TBL] [Abstract][Full Text] [Related]
13. CGG-repeat dynamics and
Zhou Y; Kumari D; Sciascia N; Usdin K
Mol Autism; 2016; 7():42. PubMed ID: 27713816
[TBL] [Abstract][Full Text] [Related]
14. Establishment of Reporter Lines for Detecting Fragile X Mental Retardation (FMR1) Gene Reactivation in Human Neural Cells.
Li M; Zhao H; Ananiev GE; Musser MT; Ness KH; Maglaque DL; Saha K; Bhattacharyya A; Zhao X
Stem Cells; 2017 Jan; 35(1):158-169. PubMed ID: 27422057
[TBL] [Abstract][Full Text] [Related]
15. FMRP ribonucleoprotein complexes and RNA homeostasis.
Suardi GAM; Haddad LA
Adv Genet; 2020; 105():95-136. PubMed ID: 32560791
[TBL] [Abstract][Full Text] [Related]
16. Fmrp Interacts with Adar and Regulates RNA Editing, Synaptic Density and Locomotor Activity in Zebrafish.
Shamay-Ramot A; Khermesh K; Porath HT; Barak M; Pinto Y; Wachtel C; Zilberberg A; Lerer-Goldshtein T; Efroni S; Levanon EY; Appelbaum L
PLoS Genet; 2015 Dec; 11(12):e1005702. PubMed ID: 26637167
[TBL] [Abstract][Full Text] [Related]
17. Integrated transcriptome analysis of human iPS cells derived from a fragile X syndrome patient during neuronal differentiation.
Lu P; Chen X; Feng Y; Zeng Q; Jiang C; Zhu X; Fan G; Xue Z
Sci China Life Sci; 2016 Nov; 59(11):1093-1105. PubMed ID: 27730449
[TBL] [Abstract][Full Text] [Related]
18. Synaptic vesicle dynamic changes in a model of fragile X.
Broek JAC; Lin Z; de Gruiter HM; van 't Spijker H; Haasdijk ED; Cox D; Ozcan S; van Cappellen GWA; Houtsmuller AB; Willemsen R; de Zeeuw CI; Bahn S
Mol Autism; 2016; 7():17. PubMed ID: 26933487
[TBL] [Abstract][Full Text] [Related]
19. BDNF in fragile X syndrome.
Castrén ML; Castrén E
Neuropharmacology; 2014 Jan; 76 Pt C():729-36. PubMed ID: 23727436
[TBL] [Abstract][Full Text] [Related]
20. Absence of the Fragile X Mental Retardation Protein results in defects of RNA editing of neuronal mRNAs in mouse.
Filippini A; Bonini D; Lacoux C; Pacini L; Zingariello M; Sancillo L; Bosisio D; Salvi V; Mingardi J; La Via L; Zalfa F; Bagni C; Barbon A
RNA Biol; 2017 Nov; 14(11):1580-1591. PubMed ID: 28640668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
